Money
Briefing: Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week
Strategic angle: The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
editorial-staff
1 min read
Updated 15 days ago
Novartis has announced the acquisition of Excellergy for $2 billion, marking a significant investment in the immunology sector. This follows a recent trend of multi-billion dollar deals within the industry.
The focus of this acquisition is on developing a next-generation allergy treatment, which is reported to have the potential for faster and more effective results compared to existing therapies.
This move could have substantial implications for the infrastructure of allergy treatment solutions, potentially enhancing throughput and capacity in the biotech landscape.